- PhaseBio Pharmaceuticals (NASDAQ:PHAS) is up 14% postmarket after reporting the completion of its Phase 2a trial of PB2452.
- More news on: PhaseBio Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
PhaseBio Pharmaceuticals Inc. Company Name:
PHAS Stock Symbol:
NASDAQ Market:
Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an upd...